A director at Texas Pacific Land Corp bought 12 shares at 1,376.900USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth Auvelity® 3Q 2024 net product sales of $80.4 million, representing 113% year-over-year growth Sunosi® 3Q 2024 net product revenue of $24.4 million representing 21% year-over-year growth Second expansion of Auvelity psychiatry sales force planned for 1Q 2025 NDA resubmission for AXS-07 for the treatment of migraine accepted by the FDA with PDUFA goal date of January 31, 2025 Topline results of ADVANCE-2 ...
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presentations spanning its innovative portfolio of late-stage products and product candidates in psychiatry and neurology at NEI Congress 2024, being held Nov. 7 - Nov. 10, 2024, in Colorado Springs, Colorado. Details for the presentations are as follows: Maj...
SuRo Capital Corp. Reports Third Quarter 2024 Financial Results Continues to Advance AI Strategy with Major New Investments Net Asset Value of $6.73 Per Share as of September 30, 2024 NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: ) today announced its financial results for the quarter ended September 30, 2024. Net assets totaled approximately $157.4 million, or $6.73 per share, at September 30, 2024, as compared to $6.94 per share at June 30, 2024 and $8.41 per share at September 30, 2023. ...
Ryman Hospitality Properties, Inc. Reports Third Quarter 2024 Results NASHVILLE, Tenn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP), a lodging real estate investment trust (“REIT”) specializing in group-oriented, destination hotel assets in urban and resort markets, today reported financial results for the three and nine months ended September 30, 2024. Third Quarter 2024 Highlights and Recent Developments: The Company generated record third quarter net income of $60.4 million and record third quarter consolidated Adjusted EBITDAre of $174.8 million....
SuRo Capital Corp. to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024 NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- (“SuRo Capital”) (Nasdaq: ) today announced that it will report its financial results for the quarter ended September 30, 2024 after the close of the U.S. market on Thursday, November 7, 2024. Management will hold a conference call and webcast for investors at 2:00 p.m. PT (5:00 p.m. ET). The conference call access number for U.S. participants is 866-580-3963, and the conference call access number for participants outside the U.S. is . The conferen...
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations from across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024, being held Oct. 29 - Nov. 2, 2024, in Boston, Massachusetts. Details for the presentations are as ...
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate...
SuRo Capital Corp. Third Quarter 2024 Preliminary Investment Portfolio Update Continues to Execute on AI Strategy with Significant New Investments Net Asset Value Anticipated to be $6.50 to $7.00 Per Share NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: ) today provided the following preliminary update on its investment portfolio for the third quarter ended September 30, 2024. “For over a decade, SuRo Capital has been the public’s gateway to curated venture capital. This access, once reserved only for ventu...
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024 Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disorders NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations on AXS-12 and solriamfetol at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society, being ...
SPX Testing Resistance as Rate Cut Cycle Begins The S&P 500 (SPX) is back to test YTD highs and important resistance in the 5670-5783 range. This is an important target/resistance area we have discussed for weeks; using the 2007 SPX topping analog which has tracked the current market almost perfectly, it would suggest a 2% or less move above the prior all-time high set in July at 5670 before topping, which is where we get the 5783 number. As long as the SPX does not have a weekly close above 57...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.